A stack: paired products.
In community usage, “stack” can mean using separately supplied components together. Their amounts remain separate.
The Wolverine Stack.
The Wolverine Stack pairs BPC-157 with a material sold as TB-500. Clinics and communities discuss tendon, ligament and joint recovery; the nickname can mean separate vials on different schedules or one fixed-ratio blend.
Research focus: Soft-tissue recovery, movement and joint-comfort interest.
Choose a compound to open its research, documentation and calculator.
QUICK REFERENCE
Checked October 15, 2026The essentials.
- FDA statusFDA status and scope
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗ - Not FDA approved
- Half-lifeHalf-life: source and route
BPC-157 has short animal IV/IM PK; a reliable human TB-500 value is not established here. A blend cannot be assigned an average half-life.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗ - Different for each componentBlend · no single half-life
- Diluent / formulationDiluent and formulation
No validated common diluent for this exact material was established by the sources reviewed here. Component recipes do not establish blend compatibility.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗ - Check the exact formulationNo universal recipe
What the documentation tells us.
Evidence context
Interest in tissue and joint recovery motivates this pairing, but the nickname is not evidence of a proven healing effect or synergy. Published component research, a small clinic report and provider descriptions answer different questions.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Component experiments, a small clinic report and named provider descriptions; the pairing’s effects are not established by its nickname.
BPC-157 is a 15-amino-acid peptide. A laboratory tendon study examined migration and growth in rat tendon cells and explants. Read the original laboratory study ↗.
A blend: one fixed ratio.
A premixed vial contains both components in a stated ratio. Every calculated portion contains both: changing the volume changes both amounts together. “Wolverine” does not tell you that ratio.
Regulator context
TB-500 and thymosin beta-4 need separate identities.
FDA’s 2026 briefing describes TB-500 as a seven-amino-acid fragment and notes inconsistent naming in marketed materials. Full-length thymosin beta-4 contains 43 amino acids. Findings about one cannot establish the effects of the other.
Read FDA’s identity assessment ↗Same nickname. Different advertised ratios.
About advertised ratios
These are named provider descriptions, not recommended formulations or independently tested contents. Clinic and supplier pages have commercial interests; inclusion is not a product endorsement.
Provider descriptions use different mass ratios. The colored bars show each component’s share of the advertised total.
CommunityClinic explainer
Moonshot Medical · 1:2
5 mg BPC-157 + 10 mg TB-500
15 mg combined mass in this description.
CommunityVendor listing
PSPeptides · 1:1
10 mg BPC-157 + 10 mg TB-500
20 mg combined mass in this listing.
Other names you may encounter: BPC TB blend, Wolverine Stack, Wolverine Blend, Wolverine peptide.
Learn to read a study →Community schedules and research routes.
Dosage & schedule options.
Reading these schedules
Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
Community guide · separate componentsSeparate vials · daily BPC-157
- Dose
- 250–500 mcg initially; then 250 mcg
- How often
- Once daily
- Route
- Subcutaneous
- Duration
- 8-week example
- Break after cycle
- Not reported
| When | Amount & frequency |
|---|---|
| Weeks 1–4 | 250–500 mcg once daily |
| Weeks 5–8 | 250 mcg once daily |
This is the BPC-157 component of the separate-vial pairing, not the combined mass of a blend.
Community guide · separate componentsSeparate vials · intermittent TB-500
- Dose
- 2.5 mg per injection
- How often
- Twice weekly initially; then once weekly
- Route
- Subcutaneous
- Duration
- 8-week example
- Break after cycle
- Not reported
| When | Amount & frequency |
|---|---|
| Weeks 1–4 | 2.5 mg twice weekly (5 mg/week) |
| Weeks 5–8 | 2.5 mg once weekly |
The TB-500 component follows a different frequency from daily BPC-157.
Reported protocolFixed 1:1 blend · five-day blocks
- Dose
- 300–500 mcg of EACH component per injection
- How often
- One injection on each treatment day: 5 days on / 2 days off
- Route
- Subcutaneous
- Duration
- 20 injections per block (4 weeks); up to 3 consecutive blocks
- Break after cycle
- 2 months after 3 blocks
Combined mass: 600–1,000 mcg (0.6–1 mg) per injection. The fixed ratio cannot reproduce different daily/weekly component schedules.
Community guideFixed 1:1 blend · six-week cycle
- Dose
- 600 mcg BPC-157 + 600 mcg TB-500 per injection
- How often
- Once/day, Monday–Friday
- Route
- Subcutaneous
- Duration
- 6 weeks
- Break after cycle
- 6 weeks
1.2 mg combined mass per injection; 3 mg of each component over a five-day week.
Community guideEqual-component capsule option
- Dose
- 500 mcg of EACH component per capsule
- How often
- Once every morning, 7 days/week
- Route
- Oral
- Duration
- Not reported
- Break after cycle
- Not reported
1 mg combined mass per capsule. An injection cycle is not assigned to this oral option.
Community guideFixed 1:1 blend · longer daily cycle
- Dose
- 0.5–1 mg of EACH component per administration
- How often
- Once daily, 5–7 days/week
- Route
- Subcutaneous
- Duration
- 6–12 weeks
- Break after cycle
- Not reported
1–2 mg combined mass per administration. This fixed-ratio option differs from the separate-vial pairing.
Community research & perspectives.
About community labels
Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.
Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.
How to read these source labels →CommunityVendor explainer
Separate-component loading and maintenance examples
PeptIQ: evidence & source context
Not a controlled trial or a representative community survey. Claims of improved combined healing are not established by the reviewed human evidence.
Source relationship: Commercial peptide-tracking app publisher.
The online guide describes an eight-week example in which BPC-157 remains daily and TB-500 changes from twice weekly to weekly.
Online proposal · separate components
CommunityClinic explainer
A clinic’s fixed-ratio Wolverine schedule
Perfect B: evidence & source context
The source calls 20 injections a month; this is four weeks at five injections weekly. It does not demonstrate clinical equivalence to separate-component schedules.
Source relationship: Commercial aesthetics and wellness provider offering the treatments discussed.
A clinic-specific blend and intermittent schedule, with its concentration arithmetic explained in the guide.
Clinic proposal · fixed-ratio blend
CommunityClinic explainer
Another provider’s blend and schedule
PeRx: evidence & source context
Its account of forum practice is not a survey. A prescribing-service description does not establish drug approval, efficacy or equivalence to a trial.
Source relationship: Commercial provider marketing the blend and related services.
PeRx describes a different concentration and six-week cycle, illustrating why the Wolverine nickname does not define one protocol.
Provider description · commercial service
CommunityClinic explainer
Route comparisons and commonly discussed pairings
Dr. Rogers Centers: evidence & source context
The daily-total table and once-or-twice-daily prose are not fully consistent. These descriptions are not trial-validated schedules.
Source relationship: Commercial clinic discussing services and proposed uses.
A clinic overview compares oral and injected BPC-157 and discusses Wolverine and other pairings. Its amounts appear in the BPC-157 dosage snapshot.
Clinic explanation · commercial treatment provider
CommunityClinic explainer
A clinic’s five-on/two-off schedule and Wolverine context
Perfect B: evidence & source context
The introductory frequency and cycle wording differs from the detailed schedule. The page does not establish that intermittent use matches daily use.
Source relationship: Commercial clinic offering the treatments described; inclusion is not an endorsement.
The detailed schedule describes once-daily use on five days per week. The article also discusses individualized Wolverine pairings.
Clinic explanation · commercial treatment provider
CommunityPublished clinic report
A small knee-pain report from a medical practice
Institute for Hormonal Balance: evidence & source context
No control group, randomization or validated outcome scale; the combination subgroup had only four people. Reported improvement cannot establish cause, safety or superiority of the combination. The abstract names thymosin beta-4, not an identified TB-500 fragment. It does not validate a subcutaneous Wolverine schedule.
Source relationship: Report from a treating medical practice. Funding and conflicts require checking in the full paper; independent funding is not established here.
This retrospective report describes knee-joint injections and telephone follow-up for 16 patients. Twelve received BPC-157 alone; four received BPC-157 with thymosin beta-4. Three of those four reported pain improvement.
Retrospective · no control group · thymosin beta-4 identity, not verified TB-500
CommunityClinic explainer
How one clinic describes a Wolverine blend
Moonshot Medical: evidence & source context
The page describes a service and proposed benefits; it does not report a controlled trial of this combination. Its ratio does not verify another product’s identity or contents.
Source relationship: Commercial clinic offering the treatment it discusses.
The clinic uses “Wolverine blend” for a combined BPC-157/TB-500 preparation and describes a 5 mg + 10 mg composition. This is one provider’s formulation, not a universal definition.
Clinic explanation · commercial treatment provider
CommunityClinic explainer
The community nickname and its recovery claims
Drip Hydration: evidence & source context
An explainer about proposed uses is different from original participant data. Recovery claims need evidence for the actual combination, material and route.
Source relationship: Commercial clinic and wellness-service provider.
This article explains how BPC-157 and TB-500 became associated with the Wolverine nickname in recovery and performance discussions.
Clinic explanation · commercial wellness services
CommunityClinic explainer
A clinic’s description of the paired components
Olympia Aesthetics: evidence & source context
Mechanism descriptions and clinical marketing do not demonstrate that the blend heals an injury or is more effective than either component.
Source relationship: Commercial aesthetics and wellness clinic.
The clinic discusses the BPC-157/TB-500 pairing under the Wolverine name. It is useful for understanding terminology readers may encounter.
Clinic explanation · commercial aesthetics services
CommunityVendor explainer
A seller’s Wolverine blend listing
PSPeptides: evidence & source context
A listing is evidence of how a product is advertised, not confirmation of its contents or clinical effectiveness. The page uses fragment and full-length thymosin terminology; molecular identity needs separate documentation.
Source relationship: Commercial supplier selling the blend; labeled for research use.
This seller lists equal-mass BPC-157/TB-500 variants, including 10 mg + 10 mg. That differs from the 1:2 ratio described by Moonshot.
Vendor description · advertised product composition
Reconstitution, storage and devices.
Product-specific handling
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
Storage: before and after opening.
BPC-157 + TB-500 · dry and prepared material
- Before opening
- Temperature and expiry: use the exact lot’s documentation. Keep the original label with the vial.
- After mixing / first use
- No universal storage window is verified in this guide. Obtain the exact preparation’s temperature and discard date.
- Handling & discard
- Record the mixing or first-puncture date. The diluent’s discard date is separate from the mixed preparation’s date.
Blend arithmetic · assumed final volume
Count each component, then the combined mass.
Reading blend concentrations
These calculations explain reported formulations; they do not establish a compatible diluent, sterility, stability or preparation recipe. A label must identify each component and its concentration. Use product-specific handling and discard instructions.
With 10 mg BPC-157 + 10 mg TB-500 in a final 2 mL, each component is 5 mg/mL; the combined concentration is 10 mg/mL. On a U-100 syringe:
6 units = 0.06 mL0.3 mg BPC-157 + 0.3 mg TB-500
10 units = 0.1 mL0.5 mg BPC-157 + 0.5 mg TB-500
1 mg combined0.5 mg of each in this 1:1 blend
The same 10-unit volume at PeRx’s stated 3 mg/mL per component would contain 0.3 mg of each. Units alone cannot identify the amount. A 1:2 blend also changes the split; enter both documented masses separately and select which component your calculator target refers to.
Explore both component amounts in the calculator ↓Habits & tracking that help.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Keep rehabilitation in the plan
A diagnosis, progressive rehabilitation and an appropriate return to activity help put pain and function changes in context.
NIAMS · injury treatment and recovery ↗Keep a consistent sleep routine
Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Record pain, movement, training load and rehabilitation together. Feeling less pain and demonstrating structural healing are different outcomes.
Documentation behind BPC-157 + TB-500.
About source checks
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
StudyBPC-157: laboratory tendon researchStudyCommunityBPC-157 with or without thymosin beta-4: retrospective clinic reportRegulatorFDA 2026 briefing: BPC-157RegulatorFDA 2026 briefing: TB-500 identity and human evidenceRegulatorWADA 2026: BPC-157 (S0) and TB-500 (S2)
Study details, timing & schedule comparisons
Online schedule context
Read the amount and its frequency together.
Evidence behind community schedules
The reviewed sources do not establish a controlled human trial validating Wolverine schedules. The small clinic report concerns knee-joint injections and thymosin beta-4, rather than a verified TB-500 fragment.
FDA’s 2026 TB-500 assessment found no human clinical studies of the identified fragment. These compounding briefings are not product approvals.
PeptIQ’s example lasts eight weeks and describes subcutaneous use. Its BPC-157 amount is a daily total. Read the complete online proposal ↗
PeRx’s overview of forum conventions instead describes 250–500 mcg BPC-157 once or twice daily. That wording is not equivalent to 250–500 mcg per day. It is the provider’s characterization of online practice, not a representative survey. Compare the provider’s wording ↗
250 mcg × 2500 mcg total per day
500 mcg × 21,000 mcg total per day
2.5 mg × 25 mg total per week, if twice weekly
Spell out “twice weekly” or “every two weeks”: “biweekly” can mean either. A broad 6–12-week range cannot establish a standard cycle or a proven washout period.
Provider comparison · fixed-ratio blends
One blend, one shared schedule.
Perfect B describes subcutaneous abdominal use at night. Local placement, bedtime and cycling rationales are source proposals; the reviewed studies do not establish a best injection site, time of day or break that improves outcomes. Read the clinic’s instructions ↗
Another provider, another schedule: PeRx describes 0.6 mg of each component per injection, Monday–Friday, for six weeks followed by six weeks off, with no loading phase. Its 3 mg/mL concentration for each component differs from Perfect B’s example. Read PeRx’s full description ↗
Every portion of a fixed-ratio blend contains both compounds. Increasing its volume to match a standalone TB-500 amount also increases BPC-157. Matching a weekly total does not establish the same effects as a different schedule.
Competitive sport: WADA’s 2026 list prohibits BPC-157 under S0 and thymosin beta-4 derivatives such as TB-500 under S2, at all times. Read the original prohibited list ↗
BPC-157 + TB-500 calculator.
About calculator examples
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
An arithmetic example
Enter the documented BPC-157 and TB-500 masses separately, then select the component your target refers to. The result shows both component amounts in the same volume. Each concentration depends on its own component mass.
YOUR CALCULATION WORKSPACE
Open focused view →Three tools. Clear numbers.
01 / YOUR INPUTS
Calculator inputsStarting numbers are worked examples, not recommended doses or preparation instructions. Dose-to-units and units-to-dose views describe the same quantities. The calculator defaults to 1 mL (100 U-100 units) of liquid added as an estimate of total solution volume.In plain EnglishChoose the amount on your vial label, the liquid you added, and the amount per dose you already want to calculate. Type an exact amount or use the slider; neither selects a dose for you.Vial → dose → syringe
CompoundSelect a name to organize your calculation. Names do not set the vial mass, target amount, or volume. NAD+ is a related compound, not a peptide. For blends, enter each component’s mass separately.In plain EnglishThis is the label on your calculation, like naming a folder. Choosing a name does not decide how much material or liquid to use.
BPC-157 mass in vialThe total mass of this compound in the vial, not its concentration. Use the mass stated in your source documentation. 1 mg = 1,000 mcg.In plain EnglishThink of mass as the amount of material you started with. Adding liquid spreads that material out; it does not create more of it. A vial marked 5 mg contains 5,000 mcg.
mg
Liquid added to the vialThe starting 1 mL (100 U-100 units) is an editable example. For a general estimate, we use the liquid added as the total solution volume; powder displacement is not included. If your preparation specifies a different final volume, enter it in Advanced. The calculator does not choose a diluent or mixing procedure.In plain English100 units on a U-100 syringe means 1 mL of liquid added; 200 units in total means 2 mL. The starting 1 mL (100 U-100 units) is an editable calculator example, not a mixing recommendation for every product. The simple calculation uses added liquid as an estimate of final volume. A correction needs data for the specific formulation, not just a peptide name. Enter a documented final volume in Advanced when available.
mL
TB-500 mass in vialEnter the documented mass of the second component. Do not divide the total blend mass unless the component ratio is known.In plain EnglishThink of mass as the amount of material you started with. Adding liquid spreads that material out; it does not create more of it. A vial marked 5 mg contains 5,000 mcg.
mg
Blend targetThe requested amount refers to the selected component. The same volume also contains the other component in the ratio specified by your vial masses.In plain EnglishA blend is like a drink with two ingredients. Choosing one ingredient for your target does not remove the other; the same portion contains some of both.
· BPC-157Amount per doseType your exact amount, or adjust the 1–20 mg slider in whole-mg steps or click a labeled value. Type decimal amounts directly in the field. The slider range is a navigation shortcut, not a recommended dose range. Amounts below 1 mg or above 20 mg can be typed directly. Switching mg/mcg preserves the amount.In plain EnglishThe amount in the vial describes the whole batch. This input describes just one portion. For example, if a 5 mg vial makes 20 equal portions, each contains 0.25 mg (250 mcg). Enter the amount from your protocol and the calculator finds the liquid volume for it.
Advanced Volume & syringe settings
Calculation basisA stated concentration is product-specific and refers to the selected blend component. It does not reveal a recoverable fill volume or establish the product’s allowed number of doses. Entering a different compound or blend component clears this concentration.In plain EnglishUse the mg/mL printed on your product label when you have it. Otherwise, you can use a documented final volume or keep the liquid-added estimate.
Syringe capacityOn a U-100 scale, 100 markings equal 1 mL. Capacity changes the displayed scale, not the concentration. These markings are not compound activity units (IU).In plain EnglishCapacity is how much liquid the syringe can hold when full. On a U-100 syringe, 10 units means 0.1 mL, and 100 units means 1 mL. A smaller syringe holds less, but each U-100 unit still means 0.01 mL.
Marked intervalRead the actual graduation spacing on your device. This setting flags values that fall between markings; it does not round the calculation or guarantee measurement accuracy.In plain EnglishThese are the steps between lines on your syringe. Like a ruler, a value can land between two lines. The calculator points that out instead of moving the answer to a nearby line.
02 / YOUR RESULTCalculated
BPC-157 + TB-500
Estimate · assumes 1 mL added = total volume
For BPC-157
U-100 syringe1 mL capacity · 100 unitsSyringe capacityAll unit conversions here use a U-100 scale: 100 units = 1 mL. The selected capacity changes the maximum volume shown, not the concentration. These are volume scale units, not compound activity units (IU).In plain EnglishCapacity is how much liquid the syringe can hold when full. On a U-100 syringe, 10 units means 0.1 mL, and 100 units means 1 mL. A smaller syringe holds less, but each U-100 unit still means 0.01 mL.
- Amount per dose
- 1 mg
- Full doses per vial Doses per vialTotal vial mass divided by the entered dose amount, rounded down to complete doses. This is a theoretical count before handling losses. It may exceed the labeled usable doses because of overfill or discard instructions. A single-dose vial is not reusable just because arithmetic shows more portions.In plain EnglishAn aliquot is just a portion. This is how many full, equally sized portions the mixture could make in perfect conditions, like counting full glasses from a pitcher.
- 5
- Syringe amount per dose Result displayBoth views describe the same calculated volume. U-100 scale units = volume in mL × 100. Changing the display does not change the concentration, target amount, or calculation. This conversion does not apply to other syringe scales or biological activity units (IU).In plain EnglishThe liquid amount stays the same when you switch views. It is like showing the same distance in centimeters or inches: only the number and label change. Here, 0.1 mL is 10 units on a U-100 syringe.
- 20units
- Amount remaining Amount remainingThe selected compound’s vial mass minus the mass in complete doses. This is a theoretical remainder, not a measured or recoverable amount; overfill, dead space, transfer losses and product discard rules are excluded.In plain EnglishAfter counting all the full doses, this is the amount left over on paper. A result of 0 mg means the amounts divide evenly; handling losses can still leave you with fewer usable doses.
- 0 mg
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
U-100 volume scaleVolume scaleThis illustration shows calculated volume against the selected capacity. It is not a physical measurement tool. The value is not rounded to the smallest marked interval.In plain EnglishThe picture helps you compare the answer with the syringe you selected. It is a drawing, so do not hold a real syringe up to your screen to measure liquid.
Illustration only · calculated value, without rounding
Concentration & remaining liquid
- Concentration ConcentrationMass divided by final solution volume. For a blend, this is the selected component’s concentration.In plain EnglishThink of juice concentrate: the same amount of concentrate in less water makes a stronger mixture. Here, mg/mL tells you how much material is in each 1 mL of liquid.
- 5 mg/mL
- Per U-100 unit Amount per scale unitOne U-100 scale unit represents 0.01 mL. This is the mass of the selected compound in that volume.In plain EnglishEach U-100 unit is a tiny portion of liquid: one hundredth of a milliliter. This number tells you how much material is inside that tiny portion.
- 50 mcg
- Full portions in vial Complete aliquotsTheoretical count of complete portions at the calculated volume. This excludes transfer loss, dead space, and any change in solution volume.In plain EnglishAn aliquot is just a portion. This is how many full, equally sized portions the mixture could make in perfect conditions, like counting full glasses from a pitcher.
- 5
- Theoretical remainder Remaining volumeMass-equivalent liquid remaining after complete portions. This is not a measured fill or recoverable volume. Handling losses, overfill and product discard rules are not included.In plain EnglishThis is a paper-and-pencil remainder: leftover compound mass expressed as liquid. It does not measure what can be recovered from the vial. Losses and product discard instructions can make the usable amount smaller.
- 0 mL
Components in 0.2 mL
BPC-1571 mg
TB-5001 mg
Saved calculations stay on this device.
See the calculation
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
CONCENTRATION → VOLUME
Dosage calculatorUse the documented concentration and an amount you already want to calculate. U-100 units are volume markings, not biological activity units or IU.Convert a known dose.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
YOUR CONVERSION
On a U-100 syringe
5units
0.05 mL · 0.25 mg
Volume = target amount ÷ concentration
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
ONE MEASUREMENT, ANOTHER UNIT
Mass, volume and activity unitsMass and volume are separate dimensions. Converting between them requires a concentration. IU describes biological activity and has no universal conversion to mg or syringe units.Keep the units clear.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
YOUR CONVERSION
1 mg equals
1,000mcg
1 g = 1,000 mg = 1,000,000 mcg
For mass → syringe volume, switch to Dosage and enter a concentration.